64 related articles for article (PubMed ID: 1944011)
21. Unexpected prevalence of hyperprolactinaemia associated with microprolactinoma and empty sella in a cohort of adult patients with non-transfusion-dependent thalassaemia: a prospective study.
Ricchi P; Ammirabile M; Spasiano A; Costantini S; Vitale M; Di Matola T; Cinque P; Filosa A; Serino D
Br J Haematol; 2014 Mar; 164(5):743-5. PubMed ID: 24251449
[No Abstract] [Full Text] [Related]
22. [Treatment of hyperprolactinemic anovulation with the dopamin-agonist quinagolide].
Koloszár S; Keresztúri A; Kovács L
Orv Hetil; 2000 Jul; 141(29):1621-3. PubMed ID: 10962898
[TBL] [Abstract][Full Text] [Related]
23. Pituitary responsiveness to luteinizing-hormone-releasing hormone in different reproductive disorders. A review.
Vasquez JM; Greenblatt RB
J Reprod Med; 1985 Aug; 30(8):591-600. PubMed ID: 3930718
[TBL] [Abstract][Full Text] [Related]
24. The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males.
De Rosa M; Ciccarelli A; Zarrilli S; Guerra E; Gaccione M; Di Sarno A; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2006 Mar; 64(3):307-13. PubMed ID: 16487441
[TBL] [Abstract][Full Text] [Related]
25. Pathological hyperprolactinemia suppresses hot flashes in menopausal women.
Scoccia B; Schneider AB; Marut EL; Scommegna A
J Clin Endocrinol Metab; 1988 Apr; 66(4):868-71. PubMed ID: 3346363
[TBL] [Abstract][Full Text] [Related]
26. Effect of long-term cabergoline therapy on the immunological pattern and pituitary function of patients with idiopathic hyperprolactinaemia positive for antipituitary antibodies.
De Bellis A; Colao A; Savoia A; Coronella C; Pasquali D; Conte M; Pivonello R; Bellastella A; Sinisi AA; Bizzarro A; Lombardi G; Bellastella G
Clin Endocrinol (Oxf); 2008 Aug; 69(2):285-91. PubMed ID: 18221394
[TBL] [Abstract][Full Text] [Related]
27. The effect of the ergoline derivative, CU 32-085, on prolactin secretion in hyperprolactinemic women.
Hesla JS; Rodman EF; Molitch ME; Goodman LA; Chang RJ
Fertil Steril; 1987 Oct; 48(4):555-9. PubMed ID: 3653414
[TBL] [Abstract][Full Text] [Related]
28. Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas.
Schwetz V; Librizzi R; Trummer C; Theiler G; Stiegler C; Pieber TR; Obermayer-Pietsch B; Pilz S
Metab Brain Dis; 2017 Feb; 32(1):155-161. PubMed ID: 27525431
[TBL] [Abstract][Full Text] [Related]
29. Osteocalcin levels in patients with microprolactinoma before and during medical treatment.
Sartorio A; Conti A; Ambrosi B; Muratori M; Morabito F; Faglia G
J Endocrinol Invest; 1990 May; 13(5):419-22. PubMed ID: 1974270
[TBL] [Abstract][Full Text] [Related]
30. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients.
Giusti M; Porcella E; Carraro A; Cuttica M; Valenti S; Giordano G
J Endocrinol Invest; 1994 Jan; 17(1):51-7. PubMed ID: 7911813
[TBL] [Abstract][Full Text] [Related]
31. Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group.
Webster J; Piscitelli G; Polli A; D'Alberton A; Falsetti L; Ferrari C; Fioretti P; Giordano G; L'Hermite M; Ciccarelli E
Clin Endocrinol (Oxf); 1992 Dec; 37(6):534-41. PubMed ID: 1286524
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas.
Knoepfelmacher M; Danilovic DL; Rosa Nasser RH; Mendonça BB
Fertil Steril; 2006 Sep; 86(3):719.e15-8. PubMed ID: 16952513
[TBL] [Abstract][Full Text] [Related]
33. A study of pineal-prolactin interaction: prolactin response to an acute melatonin injection in patients with hyperprolactinemia.
Lissoni P; Mainini E; Mazzi C; Cattaneo G; Barni S
J Endocrinol Invest; 1990 Feb; 13(2):85-9. PubMed ID: 2329263
[TBL] [Abstract][Full Text] [Related]
34. [Prolactin, gonadotropic hormone and estradiol secretion in the hyperprolactinemia syndrome].
Balabolkin MI; Gerasimov GA; Gincherman LE; Chernova TO
Sov Med; 1988; (6):17-9. PubMed ID: 3187666
[No Abstract] [Full Text] [Related]
35. Interpretation of Serum Gonadotropin Levels in Hyperprolactinaemia.
Abbara A; Clarke SA; Nesbitt A; Ali S; Comninos AN; Hatfield E; Martin NM; Sam AH; Meeran K; Dhillo WS
Neuroendocrinology; 2018; 107(2):105-113. PubMed ID: 29660734
[TBL] [Abstract][Full Text] [Related]
36. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group.
Webster J; Piscitelli G; Polli A; D'Alberton A; Falsetti L; Ferrari C; Fioretti P; Giordano G; L'Hermite M; Ciccarelli E
Clin Endocrinol (Oxf); 1993 Sep; 39(3):323-9. PubMed ID: 7900937
[TBL] [Abstract][Full Text] [Related]
37. Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration.
Sonigo C; Bouilly J; Carré N; Tolle V; Caraty A; Tello J; Simony-Conesa FJ; Millar R; Young J; Binart N
J Clin Invest; 2012 Oct; 122(10):3791-5. PubMed ID: 23006326
[TBL] [Abstract][Full Text] [Related]
38. Ectopic posterior pituitary causing hyperprolactinemia.
Iacovazzo D; Lugli F; Giampietro A
Endocrine; 2012 Oct; 42(2):449-50. PubMed ID: 22733394
[No Abstract] [Full Text] [Related]
39. Synchronous endometrial carcinoma and a macroprolactinoma: exploring a causal relationship.
Sharma A; Sharma MS; De Padua M; Jha UP; Jha AN
Oncology; 2007; 72(1-2):139-42. PubMed ID: 18025806
[TBL] [Abstract][Full Text] [Related]
40. Continuous bromocriptine treatment of empty sella syndrome aggravating pregnancy. A case report.
Georgiev DB; Dokumov SI
Gynecol Obstet Invest; 1991; 32(4):243-4. PubMed ID: 1778518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
